Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers are calling for standardized guidelines to manage neonates with HDFN. Postnatal ...

Early-onset severe hemolytic disease of the fetus and newborn, defined as occurring before 24 weeks’ gestation, is typically associated with substantial fetal and neonatal morbidity and ...

Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN) ...

In early-onset severe hemolytic disease of the fetus and newborn (HDFN), transplacental transfer of maternal antierythrocyte IgG alloantibodies causes fetal anemia that leads to the use of high ...

is used for severe hemolytic disease of the newborn. Partial or dilutional exchange transfusion, done for polycythemia, consists of removing whole blood and replacing it milliliter for milliliter ...

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent ... placebo Nipocalimab was granted BTD in hemolytic disease of the fetus and newborn ...

Harrison’s plasma contained a rare antibody, known as anti-D, which is used to make injections that protect unborn babies from hemolytic disease of the newborn, in which a pregnant woman’s ...

It's used to make injections that protect unborn babies from hemolytic disease of the newborn, in which a pregnant woman's immune system attacks her fetus' red blood cells. The disease is most ...